SCOPUS 정보 검색 플랫폼

Australian and New Zealand Journal of Medicine

Volumn 29, Issue 3, 1999, Pages 371-372

Olanzapine: Extrapyramidal side effects in the elderly

(2) Granger, A S a Hanger, H C a

a PRINCESS MARGARET HOSPITAL (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA PLUS LEVODOPA; CHLORPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE;

AGED; AGING; ARTICLE; CASE REPORT; DEPRESSION; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HALLUCINATION; HUMAN; IMMOBILIZATION; MALE; PARKINSON DISEASE; PSYCHOSIS; RIGIDITY; SCHIZOPHRENIA;

EID: 0033063136 PISSN: 00048291 EISSN: None Source Type: Journal
DOI: 10.1111/j.1445-5994.1999.tb00722.x Document Type: Article

Times cited : (7)

References (9)

1
- 0028331326
- The new atypical antipsychotics: A lack of extrapyramidal side effects and new routes in schizophrenia research
- 1. Kerwin RW. The new atypical antipsychotics: A lack of extrapyramidal side effects and new routes in schizophrenia research. Br J Psych 1994; 164: 141-8.
- (1994) Br J Psych , vol.164 , pp. 141-148
- Kerwin, R.W.¹

2
- 0030944923
- Olanzapine: A new atypical neuroleptic agent
- 2. Reus VI. Olanzapine: a new atypical neuroleptic agent. Lancet 1997; 349: 1264-5.
- (1997) Lancet , vol.349 , pp. 1264-1265
- Reus, V.I.¹

3
- 0030965787
- Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia
- 3. Tran PV, Dellva MA, Tollefson GD, Beasley CM, Potvin JH, Kiesler GM. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry 1997; 58: 205-11.
- (1997) J Clin Psychiatry , vol.58 , pp. 205-211
- Tran, P.V.¹ Dellva, M.A.² Tollefson, G.D.³ Beasley, C.M.⁴ Potvin, J.H.⁵ Kiesler, G.M.⁶

4
- 0031949643
- Olanzapine can worsen parkinsonism
- 4. Jimenez-Jimenez FJ, Tallon-Barranco A, Orti-Pareja M, Zurdo M, Porta J, Molina JA. Olanzapine can worsen parkinsonism. Neurology 1998; 50: 1183-4.
- (1998) Neurology , vol.50 , pp. 1183-1184
- Jimenez-Jimenez, F.J.¹ Tallon-Barranco, A.² Orti-Pareja, M.³ Zurdo, M.⁴ Porta, J.⁵ Molina, J.A.⁶

5
- 85046223407
- Olanzapine in the treatment of dopaminometic psychosis in patients with Parkinson's disease
- 5. Friedman J. Olanzapine in the treatment of dopaminometic psychosis in patients with Parkinson's disease. Neurology 1998; 50: 1195-6.
- (1998) Neurology , vol.50 , pp. 1195-1196
- Friedman, J.¹

6
- 0031694828
- Speech disturbance and marked decrease in function in several older patients on olanzapine
- 6. Gaile S, Noviasky JA. Speech disturbance and marked decrease in function in several older patients on olanzapine. JAGS 1998; 10: 1330.
- (1998) JAGS , vol.10 , pp. 1330
- Gaile, S.¹ Noviasky, J.A.²

7
- 0029930337
- Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial
- 7. Beasley CM, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 1996; 124: 159-67.
- (1996) Psychopharmacology , vol.124 , pp. 159-167
- Beasley, C.M.¹ Sanger, T.² Satterlee, W.³ Tollefson, G.⁴ Tran, P.⁵ Hamilton, S.⁶

8
- 0030065502
- Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial
- 8. Beasley CM, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14: 111-23.
- (1996) Neuropsychopharmacology , vol.14 , pp. 111-123
- Beasley, C.M.¹ Tollefson, G.² Tran, P.³ Satterlee, W.⁴ Sanger, T.⁵ Hamilton, S.⁶

9
- 12944308876
- 9. Eli Lilly and Company. Olanzapine - prescribing information.
- Olanzapine - Prescribing Information
- Lilly, E.¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.